BioNTech’s Q3 revenue surged to €1.244 billion, reflecting early COVID-19 vaccine approvals. Net profit rose to €198.1 million, and full-year guidance adjusted downward.
BioNTech Variant-adapted COVID-19 Vaccines Do Well In Q3
Where Today's News Shapes Tomorrow
